An interventional study of Placebo (Sodium Chloride) and Exercise in Obesity, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by Imperial College London · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Obesity by Imperial College London — 5 open to participants now, 6 under way, none of them phase 3. Obesity · Imperial College London.
Among the 36 studies in Obesity by Imperial College London, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2018, is one of 21 with no phase, and was the 30th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 36 studies in Obesity by Imperial College London are open now, in 2 countries. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
Imperial College London · Sites in Ireland
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–70 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–75
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 1
First in 2008; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 53 across the 27 interventional studies, 100 across the 9 observational. Of the 25 that completed or were terminated, 19 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Obesity by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432025Imperial College LondonMedication Following Bariatric Surgery for Type 2 Diabetes Mellitus | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Obesity by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The research project aims to examine the effect of a dietary supplement called propionate on how the human body in healthy adults aged (18- 65 years) responds to during fasting, exercise and following a liquid mixed meal test and how that would affect energy homeostasis and substrate oxidation.
Dietary fibres have long been recognised for their important role in a healthy diet due to their negative association with, and even management of, chronic diseases such as obesity, diabetes, metabolic syndrome, cardiovascular disease and inflammatory-bowel disease among others.Emerging evidence has suggested that these benefits could largely be attributed to short chain fatty acids (SCFA) (acetate, propionate and butyrate), the main by-products of fibre fermentation in the gut. Previous research has demonstrated that a long-term elevation in the SCFA propionate significantly reduced body weight gain in overweight adults and reduced liver fat storage.
The current project will examine potential mechanisms for the positive effect of propionate on energy homeostasis and metabolic profile.The effects of propionate on circulating glucose, insulin, gut hormones and lipid levels at rest, following moderate-intensity exercise and mixed meal tolerance test will be examined.
To acutely increase propionate absorption from the gut the present project will use a simple nutritional supplement: sodium propionate in a hydroxypropylmethyl cellulose (HPMC) capsule. This capsule is coated with an enteric film which prevents gastric digestion until the capsule reaches the intestine. This nutritional supplement has been used in human volunteers in a previously approved ethics application (12/LO/1769: Oral propionate and glucose homeostasis). A 5g acute dose of sodium propionate had previously been tested and reported no adverse effects . The MHRA have confirmed that encapsulated sodium propionate is not classed as an investigative medicinal product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sodium Chloride tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
Other: Placebo (Sodium Chloride)
Sodium Chloride tested in an exercise state. Participants will have the placebo then exercise will be performed at 40% of maximal aerobic capacity for one hour.
Other: Placebo (Sodium Chloride) · Other: Exercise
Sodium Chloride tested in a post-prandial state. Participants will have the placebo then a mixed liquid meal test is given.
Other: Placebo (Sodium Chloride)
Sodium Propionate tested in a fasting state. Participants will be fasting for duration of study visit (360 minutes).
Dietary Supplement: Sodium Propionate
Sodium Propionate tested in an exercise state. Participants will have the sodium propionate then exercise will be performed at 40% of maximal aerobic capacity for one hour.
Other: Exercise · Dietary Supplement: Sodium Propionate
Sodium Propionate tested in a post-prandial state. Participants will have the sodium propionate then a mixed liquid meal test is given.
Dietary Supplement: Sodium Propionate
Participant receive Placebo (Sodium Chloride)
1 hour exercise
Participant receive Sodium Propionate
Changes in Resting Energy Expenditure
Changes in Resting Energy Expenditure between sodium propionate and sodium chloride (control).
Time frame: 6 hours
Changes in Resting Lipid Oxidation
Changes in Resting Lipid Oxidation between sodium propionate and sodium chloride (control).
Time frame: 6 hours
Changes in Energy Expenditure During Exercise
Changes in Energy Expenditure between sodium propionate and sodium chloride (control) during exercise.
Time frame: 240 minutes
Changes in Lipid Oxidation During Exercise
Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) during exercise.
Time frame: 240 minutes
Changes in Energy Expenditure Post-prandially
Changes in Energy Expenditure between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Lipid Oxidation Post-prandially
Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Glucose Concentrations Post-prandially
Changes in glucose concentrations between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Glucose Concentrations During Exercise
Changes in glucose concentrations between sodium propionate and sodium chloride (control) during exercise.
Time frame: 240 minutes
Changes in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm).
Changes in subjective thirst between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
Time frame: 300 minutes
Changes in Subjective Thirst During Exercise With Visual Analog Scales (100 mm)
Changes in subjective thirst between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
Time frame: 240 minutes
Changes in Subjective Nausea During Exercise With Visual Analog Scales (100 mm)
Changes in subjective nausea between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.
Time frame: 240 minutes
Changes in Subjective Hunger During Exercise With Visual Analog Scales (100 mm)
Changes in subjective hunger between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
Time frame: 240 minutes
Changes in GLP-1 Concentration
Changes in GLP-1 concentrations between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Insulin Concentration
Changes in insulin concentrations between sodium propionate and sodium chloride (control) during fasting
Time frame: 360 minutes
Changes in Glucose Concentration
Changes in glucose concentrations between sodium propionate and sodium chloride (control) during fasting
Time frame: 360 minutes
Changes in Free Fatty Acid Concentration
Changes in free fatty acid concentrations between sodium propionate and sodium chloride (control) during fasting
Time frame: 360 minutes
Changes in Subjective Nausea With Visual Analog Scales (100 mm)
Changes in subjective nausea between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.
Time frame: 360 minutes
Changes in Subjective Hunger With Visual Analog Scales (100 mm)
Changes in subjective hunger between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
Time frame: 360 minutes
Changes in Subjective Thirst Using Visual Analog Scales (100 mm)
Changes in subjective thirst between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
Time frame: 360 minutes
Changes in Insulin Concentration
Changes in insulin concentrations between sodium propionate and sodium chloride (control) during exercise
Time frame: 240 minutes
Changes in Insulin Concentration
Changes in insulin concentrations between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially
Changes in subjective nausea between sodium propionate and sodium chloride (control) post-prandially.
Time frame: 300 minutes
Changes in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm)
Changes in subjective hunger between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
Time frame: 300 minutes
| Milestone | Fasted Study: Placebo/Propionate | Fasted Study: Propionate/Placebo | Post-Prandial Study: Placebo/Propionate | Post-Prandial Study: Propionate/Placebo | Exercise Study: Placebo/Propionate | Exercise Study: Propionate/Placebo |
|---|---|---|---|---|---|---|
| Started | 12 | 13 | 0 | 0 | 0 | 0 |
| Completed | 10 | 9 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 4 | 0 | 0 | 0 | 0 |
| Milestone | Fasted Study: Placebo/Propionate | Fasted Study: Propionate/Placebo | Post-Prandial Study: Placebo/Propionate | Post-Prandial Study: Propionate/Placebo | Exercise Study: Placebo/Propionate | Exercise Study: Propionate/Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 12 | 13 | 0 | 0 |
| Completed | 0 | 0 | 9 | 11 | 0 | 0 |
| Not completed | 0 | 0 | 3 | 2 | 0 | 0 |
| Milestone | Fasted Study: Placebo/Propionate | Fasted Study: Propionate/Placebo | Post-Prandial Study: Placebo/Propionate | Post-Prandial Study: Propionate/Placebo | Exercise Study: Placebo/Propionate | Exercise Study: Propionate/Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 12 |
| Completed | 0 | 0 | 0 | 0 | 10 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 3 | 3 |
Changes in Resting Energy Expenditure between sodium propionate and sodium chloride (control).
| kcal/min | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Resting Energy Expenditure | 1.013 ± 0.034 | 1.040 ± 0.039 |
Changes in Resting Lipid Oxidation between sodium propionate and sodium chloride (control).
| g/min | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Resting Lipid Oxidation | 0.032 ± 0.007 | 0.042 ± 0.007 |
Changes in Energy Expenditure between sodium propionate and sodium chloride (control) during exercise.
| kcal/min | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Energy Expenditure During Exercise | 5.085 ± 0.330 | 4.991 ± 0.328 |
Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) during exercise.
| g/min | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Lipid Oxidation During Exercise | 0.284 ± 0.032 | 0.287 ± 0.030 |
Changes in Energy Expenditure between sodium propionate and sodium chloride (control) post-prandially.
| kcal/min | Placebo + Post-prandial | Propionate and Post-prandial |
|---|---|---|
| Changes in Energy Expenditure Post-prandially | 1.057 ± 0.044 | 1.072 ± 0.046 |
Changes in Lipid Oxidation between sodium propionate and sodium chloride (control) post-prandially.
| g/min | Placebo + Post-prandial | Propionate and Post-prandial |
|---|---|---|
| Changes in Lipid Oxidation Post-prandially | 0.027 ± 0.005 | 0.025 ± 0.005 |
Changes in glucose concentrations between sodium propionate and sodium chloride (control) post-prandially.
| mmol/L | Placebo + Post-prandial | Propionate and Post-prandial |
|---|---|---|
| Changes in Glucose Concentrations Post-prandially | 5.38 ± 0.133 | 5.40 ± 0.141 |
Changes in glucose concentrations between sodium propionate and sodium chloride (control) during exercise.
| mmol/L | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Glucose Concentrations During Exercise | 4.35 ± 0.09 | 4.47 ± 0.07 |
Changes in subjective thirst between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
| mm | Placebo + Post-prandial | Propionate and Post-prandial |
|---|---|---|
| Changes in Subjective Thirst Post-prandially Using a Visual Analog Scale (100 mm). | 15.7 ± 4.3 | 14.5 ± 4.0 |
Changes in subjective thirst between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
| mm | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Subjective Thirst During Exercise With Visual Analog Scales (100 mm) | 39.8 ± 5.3 | 46.8 ± 5.4 |
Changes in subjective nausea between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.
| mm | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Subjective Nausea During Exercise With Visual Analog Scales (100 mm) | 2.9 ± 1.1 | 6.7 ± 3.4 |
Changes in subjective hunger between sodium propionate and sodium chloride (control) during exercise. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
| mm | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Subjective Hunger During Exercise With Visual Analog Scales (100 mm) | 51.7 ± 5.7 | 57.2 ± 5.3 |
Changes in GLP-1 concentrations between sodium propionate and sodium chloride (control) post-prandially.
| mmol/L | Placebo + Postprandial | Propionate and Postprandial |
|---|---|---|
| Changes in GLP-1 Concentration | 67.9 ± 7.1 | 70.5 ± 6.2 |
Changes in insulin concentrations between sodium propionate and sodium chloride (control) during fasting
| μU/mL | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Insulin Concentration | 7.70 ± 0.48 | 7.87 ± 0.59 |
Changes in glucose concentrations between sodium propionate and sodium chloride (control) during fasting
| mmol/L | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Glucose Concentration | 4.12 ± 0.08 | 4.14 ± 0.08 |
Changes in free fatty acid concentrations between sodium propionate and sodium chloride (control) during fasting
No measurements were reported for this outcome.
Changes in subjective nausea between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective nausea. High (100 mm) mean high subjective nausea.
| mm | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Subjective Nausea With Visual Analog Scales (100 mm) | 48.0 ± 4.11 | 44.8 ± 5.25 |
Changes in subjective hunger between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
| mm | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Subjective Hunger With Visual Analog Scales (100 mm) | 48.0 ± 4.11 | 44.8 ± 5.25 |
Changes in subjective thirst between sodium propionate and sodium chloride (control) during fasting. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective thirst. High (100 mm) mean high subjective thirst.
| mm | Placebo + Fasting | Propionate and Fasting |
|---|---|---|
| Changes in Subjective Thirst Using Visual Analog Scales (100 mm) | 24.7 ± 5.43 | 23.2 ± 5.25 |
Changes in insulin concentrations between sodium propionate and sodium chloride (control) during exercise
| μU/mL | Placebo + Exercise | Propionate and Exercise |
|---|---|---|
| Changes in Insulin Concentration | 5.34 ± 0.39 | 5.63 ± 0.55 |
Changes in insulin concentrations between sodium propionate and sodium chloride (control) post-prandially.
| μU/mL | Placebo + Post-prandial | Propionate and Postprandial |
|---|---|---|
| Changes in Insulin Concentration | 29.88 ± 2.69 | 30.27 ± 2.17 |
Changes in subjective nausea between sodium propionate and sodium chloride (control) post-prandially.
| mm | Placebo + Postprandial | Propionate and Postprandial |
|---|---|---|
| Changes in Subjective Nausea Between Sodium Propionate and Sodium Chloride Post-prandially | 4.7 ± 1.8 | 5.3 ± 1.8 |
Changes in subjective hunger between sodium propionate and sodium chloride (control) post-prandially. Volunteers completed the visual analog scale using a pen (Biro, black) with scales printed (Sharp MX-7580N ) on paper (A4, white). Visual analog scales were 100 mm in length. Minimum (0 mm) mean low subjective hunger. High (100 mm) mean high subjective hunger.
| mm | Placebo + Postprandial | Propionate and Postprandial |
|---|---|---|
| Changes in Subjective Hunger Between Sodium Propionate and Sodium Chloride Post-prandially With Visual Analog Scales (100 mm) | 48.8 ± 5.0 | 43.7 ± 5.4 |
Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Fasting Then Propionate and Fasting | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Placebo + Exercise Then Propionate and Exercise | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Placebo + Postprandial Then Propionate and Postprandial | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
Baseline analysis of 'new' participants - first assigned study.
| Age, Categorical(Participants) | Fasted Study | Post-prandial Study | Exercise Study | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 16 | 12 | 53 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Fasted Study | Post-prandial Study | Exercise Study | Total |
|---|---|---|---|---|
| Female | 12 | 7 | 4 | 23 |
| Male | 13 | 9 | 8 | 30 |
| Race and Ethnicity Not Collected(Participants) | Fasted Study | Post-prandial Study | Exercise Study | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(participants) | Fasted Study | Post-prandial Study | Exercise Study | Total |
|---|---|---|---|---|
| United Kingdom | 25 | 16 | 12 | 53 |
| BMI(kg/m^2) | Fasted Study | Post-prandial Study | Exercise Study | Total |
|---|---|---|---|---|
| Mean | 23.1 ± 0.7 | 24.7 ± 0.8 | 24.5 ± 0.7 | 24.1 ± 0.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There is not a plan to make IPD available
Ran from Feb 2018 to primary completion in Aug 2019, 17 months.
Results were first posted in Aug 2024, 5 years after primary completion.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 17 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium propionate